Abstract

BackgroundAntinuclear antibodies (ANA), smooth muscle antibodies (SMA) and antibodies to a soluble liver antigen/liver pancreas (anti-SLA/LP) are useful markers that can help clinicians to diagnose and classify autoimmune hepatitis (AIH).ObjectivesTo determine whether ANA, SMA and anti-SLA/LP help to accurately diagnose patients with AIH.Search strategyThe PubMed, CNKI, WANFANG, and SinoMed databases were accessed to retrieve studies published in English and Chinese. Studies published up to October 2013 were reviewed.Selection criteriaStudies on the diagnostic value of ANA, SMA or anti-SLA/LP in the diagnosis of known or suspected AIH were included.Data collection and analysisTwo authors evaluated studies independently and rated their methodological quality using quality assessment of diagnostic accuracy studies (QUADAS) tools; relevant data were abstracted. The random-effects method was used to summarize sensitivities, specificities, positive and negative likelihood ratios, and diagnostic odds ratios (DORs) from all 29 studies.ResultsThe pooled sensitivity, specificity, positive and negative likelihood ratios, and DOR for ANA were 0.650 (95% confidence interval [CI], 0.619 to 0.680), 0.751 (95%CI, 0.737 to 0.764), 3.030 (95%CI, 2.349 to 3.910), 0.464 (95%CI, 0.356 to 0.604), and 7.380 (95%CI, 4.344 to 12.539), respectively. For SMA, the values were 0.593 (95%CI, 0.564 to 0.621), 0.926 (95%CI, 0.917 to 0.934), 11.740 (95%CI, 7.379 to 18.678), 0.449 (95%CI, 0.367 to 0.549), and 31.553 (95%CI, 17.147 to 58.060), respectively. Finally, for anti-SLA/LP, the values were 0.194 (95%CI, 0.168 to 0.222), 0.989 (95%CI, 0.985 to 0.993), 11.089 (95%CI, 7.601 to 16.177), 0.839 (95%CI, 0.777 to 0.905), and 16.867 (95%CI, 10.956 to 25.967), respectively.Authors’ conclusionsANA provided moderate sensitivity and specificity, while SMA gave moderate sensitivity and high specificity, and anti-SLA/LP exhibited low sensitivity and high specificity. All three antibodies were limited by their unsatisfactory sensitivities and lack of consistency.

Highlights

  • Autoimmune hepatitis (AIH) was first used as a descriptive term in 1965 [1], it has been researched extensively, no cure has yet been found

  • We used the standards of the International Autoimmune Hepatitis Group (IAIHG) [8,9] and the guideline approved by the American Association for the Study of Liver Diseases (AASLD) [16,17] as reference standards for autoimmune hepatitis (AIH)

  • Eighteen studies on 968 patients investigated the diagnostic accuracy of Antinuclear antibodies (ANA) [45,46,47,50,52,54,59,60,61,62,64,65,66,67,68,70,71,73], 22 studies on 1,193 patients reported on the diagnostic accuracy of smooth muscle antibodies (SMA) [46,47,50,52,53,54,55,57,58,59,60,61,62,63,64,65,67,68,69,70,71,73], and 16 studies on 850 patients focused on the diagnostic accuracy of anti-Soluble liver antigen (SLA)/liver pancreas (LP) [46,47,48,49,50,51,52,56,60,63,65,68,69,70,72,73]

Read more

Summary

Introduction

Autoimmune hepatitis (AIH) was first used as a descriptive term in 1965 [1], it has been researched extensively, no cure has yet been found. The etiology of AIH is unknown, but both the genetic composition of particular population groups and environmental exposures are involved in its expression. AIH is associated with particular human leucocyte antigens (HLA) alleles, with the ancestral B8-DR3 haplotype and DR4 [4,5,6,7]. AIH is extremely responsive to immunosuppressive therapy [7,19]. Antinuclear antibodies (ANA), smooth muscle antibodies (SMA) and antibodies to a soluble liver antigen/liver pancreas (anti-SLA/LP) are useful markers that can help clinicians to diagnose and classify autoimmune hepatitis (AIH)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call